Kimryn Rathmell: Engineering a STING Agonist-Powered Immune Response with Nanobody Conjugates
Kimryn Rathmell, CEO of Ohio State’s James Cancer Hospital and Solove Research Institute, shared a post on X by Immunoengineering Lab, about a paper she co-authored with colleagues published in Nature Biomedical Engineering:
“Delighted to see this in print, and glad to have been on the team. Super cool science with immediate implications for treatment paradigms – using nanobodies to engineer a STING agonist-powered response of the innate immune system to cancer. Congrats, Immunoengineering Lab, and well done!”
Quoting Immunoengineering Lab’s post:
“Excited to share our latest publication in Nature Biomedical Engineering! Big congrats to all co-authors on this highly collaborative effort – especially to the first author, Blaise Kimmel, for his dedication to this project! Check out the paper (open access).”
Title: Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody–STING agonist conjugates
Authors: Blaise R. Kimmel, Karan Arora, Neil C. Chada, Vijaya Bharti, Alexander J. Kwiatkowski, Jonah E. Finkelstein, Ann Hanna, Emily N. Arner, Taylor L. Sheehy, Lucinda E. Pastora, Jinming Yang, Hayden M. Pagendarm, Payton T. Stone, Ebony Hargrove-Wiley, Brandie C. Taylor, Lauren A. Hubert, Barbara M. Fingleton, Katherine N. Gibson-Corley, Jody C. May, John A. McLean, Jeffrey C. Rathmell, Ann Richmond, W. Kimryn Rathmell, Justin M. Balko, John T. Wilson
You can read the Full Article in Nature Biomedical Engineering.
More posts featuring Kimryn Rathmell.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023